BCG vaccine - PT Bio Farma
Latest Information Update: 26 Sep 2022
At a glance
- Originator PT Bio Farma
- Class Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Tuberculosis
Most Recent Events
- 30 Jul 2022 PT Bio Farma completes a Phase-II clinical trial in Tuberculosis (Prevention, In infants, In neonates) in Indonesia (Intradermal) (NCT05124340)
- 01 Dec 2021 Phase-II clinical trials in Tuberculosis (Prevention) in Indonesia (Intradermal) (NCT05124340)
- 17 Nov 2021 PT Bio Farma plans a phase II trial for Tuberculosis (Prevention, In infants) (Intradermal, Injection), in December 2021 (NCT05124340)